Newron Pharmaceuticals - Evenamide licence agreement in Japan
Newron has entered into a licence agreement with EA Pharma, a subsidiary of Eisai, to develop, manufacture and commercialise evenamide, Newron’s...
631 Views
Newron Pharmaceuticals - Moving full steam towards pivotal studies
Newron Pharmaceuticals’ H124 results reflect a period of positive traction for lead clinical asset evenamide, with stellar clinical data as an...
249 Views
Newron Pharmaceuticals - Evenamide road to registration and beyond
Newron hosted an investor day (25 June) featuring three key opinion leaders (KOLs) who highlighted evenamide’s unique mechanism at the site of...
374 Views
Newron Pharmaceuticals - Evenamide potential for treatment of schizophrenia
Newron Pharmaceuticals has released additional data from its Phase II/III trial (study 008A), providing further evidence to support evenamide’s...
285 Views
Newron Pharmaceuticals - Evenamide notches up another win (study 008A)
Newron Pharmaceuticals has shared positive top-line data for its evenamide programme from its potentially pivotal Phase II/III trial (study 008A)...
222 Views